miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis

The in-stent restenosis (IRS) after the percutaneous coronary intervention contributes to the major treatment failure of stent implantation. MicroRNAs have been revealed as powerful gene medicine to regulate endothelial cells (EC) and smooth muscle cells (SMC) in response to vascular injury, providi...

Full description

Saved in:
Bibliographic Details
Published inBioactive materials Vol. 6; no. 12; pp. 4686 - 4696
Main Authors Wang, Jing, Qian, Hong-Lin, Chen, Sheng-Yu, Huang, Wei-Pin, Huang, Dan-Ni, Hao, Hong-Ye, Ren, Ke-Feng, Wang, Yun-Bing, Fu, Guo-Sheng, Ji, Jian
Format Journal Article
LanguageEnglish
Published China Elsevier B.V 01.12.2021
KeAi Publishing
KeAi Communications Co., Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The in-stent restenosis (IRS) after the percutaneous coronary intervention contributes to the major treatment failure of stent implantation. MicroRNAs have been revealed as powerful gene medicine to regulate endothelial cells (EC) and smooth muscle cells (SMC) in response to vascular injury, providing a promising therapeutic candidate to inhibit IRS. However, the controllable loading and eluting of hydrophilic bioactive microRNAs pose a challenge to current lipophilic stent coatings. Here, we developed a microRNA eluting cardiovascular stent via the self-healing encapsulation process based on an amphipathic poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) (PCL-PEG-PCL, PCEC) triblock copolymer spongy network. The miR-22 was used as a model microRNA to regulate SMC. The dynamic porous coating realized the uniform and controllable loading of miR-22, reaching the highest dosage of 133 pmol cm−2. We demonstrated that the sustained release of miR-22 dramatically enhanced the contractile phenotype of SMC without interfering with the proliferation of EC, thus leading to the EC dominating growth at an EC/SMC ratio of 5.4. More importantly, the PCEC@miR-22 coated stents showed reduced inflammation, low switching of SMC phenotype, and low secretion of extracellular matrix, which significantly inhibited IRS. This work provides a simple and robust coating platform for the delivery of microRNAs on cardiovascular stent, which may extend to other combination medical devices, and facilitate practical application of bioactive agents in clinics. [Display omitted] •Amphipathic PCL-PEG-PCL triblock copolymer was used to prepare dynamic porous coating.•MicroRNA miR-22 was loaded into the coating through a self-healing encapsulation process.•The miR-22 coating enhanced contractile phenotype and suppressed proliferation of SMCs.•The stent with the miR-22 coating showed significant capability to inhibit in-stent restenosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2452-199X
2452-199X
DOI:10.1016/j.bioactmat.2021.04.037